--- title: "Engaging In Insider Activity, Sam Samad At IDEXX Laboratories Exercises Options Worth $0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286585689.md" description: "Sam Samad, a Board Member at IDEXX Laboratories, exercised stock options for 0 shares at an exercise price of $0.0, as disclosed in a recent SEC filing. IDEXX shares are currently trading at $532.0, reflecting a 0.47% increase. The company reported a revenue growth rate of 14.26% and a gross margin of 63.35%, indicating strong financial performance despite a higher debt-to-equity ratio of 0.71." datetime: "2026-05-15T15:02:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286585689.md) - [en](https://longbridge.com/en/news/286585689.md) - [zh-HK](https://longbridge.com/zh-HK/news/286585689.md) --- # Engaging In Insider Activity, Sam Samad At IDEXX Laboratories Exercises Options Worth $0 A large exercise of company stock options by **Sam Samad**, Board Member at **IDEXX Laboratories** (NASDAQ:IDXX) was disclosed in a new SEC filing on May 14, as part of an insider exercise. **What Happened:** A Form 4 filing with the U.S. Securities and Exchange Commission on Thursday revealed that Samad, Board Member at IDEXX Laboratories in the Health Care sector, exercised stock options for 0 shares of IDXX stock. The exercise price of the options was $0.0 per share. Currently, **IDEXX Laboratories** shares are trading up 0.47%, priced at $532.0 during Friday's morning. This values Samad's 0 shares at $0. ### Discovering IDEXX Laboratories: A Closer Look Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States. ### Unraveling the Financial Story of IDEXX Laboratories **Revenue Growth:** IDEXX Laboratories's remarkable performance in 3 months is evident. As of 31 March, 2026, the company achieved an impressive revenue growth rate of **14.26%**. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector. **Insights into Profitability:** - Gross Margin: The company excels with a remarkable gross margin of 63.35%, indicating superior cost efficiency and profitability compared to its industry peers. - Earnings per Share (EPS): IDEXX Laboratories's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 3.5. **Debt Management:** IDEXX Laboratories's debt-to-equity ratio stands notably higher than the industry average, reaching **0.71**. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage. **Understanding Financial Valuation:** - Price to Earnings (P/E) Ratio: The current P/E ratio of 39.21 is below industry norms, indicating potential undervaluation and presenting an investment opportunity. - Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 9.66 as compared to the industry average, the stock might be considered overvalued based on sales performance. - EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): At 27.57, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance. **Market Capitalization:** Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position. ### Unmasking the Significance of Insider Transactions Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria. In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction. When a company insider makes a new purchase, that is an indication that they expect the stock to rise. Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. ### Breaking Down the Significance of Transaction Codes Taking a closer look at transactions, investors often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A **P** in Box 3 denotes a purchase, while **S** signifies a sale. Transaction code **C** denotes the conversion of an option, and transaction code **A** signifies a grant, award, or other acquisition of securities from the company. Check Out The Full List Of IDEXX Laboratories's Insider Trades. _This article was generated by Benzinga's automated content engine and reviewed by an editor._ ### Related Stocks - [IDXX.US](https://longbridge.com/en/quote/IDXX.US.md) ## Related News & Research - [IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day | IDXX Stock News](https://longbridge.com/en/news/286464576.md) - [Elyxium Wealth LLC Invests $3.67 Billion in IDEXX Laboratories, Inc. $IDXX](https://longbridge.com/en/news/286734491.md) - [Stock + Option Selling Myth: More Premium Does Not Always Mean a Better Trade](https://longbridge.com/en/news/286649178.md) - [OpenAI's chip partner Cerebras hit Wall Street, and that means a big payday for Sam Altman](https://longbridge.com/en/news/286457703.md) - [World Copper Announces TSXV Acceptance for Brassie Creek Option Agreement | WCUFF Stock News](https://longbridge.com/en/news/287001580.md)